carbon monoxide and bay 63-2521

carbon monoxide has been researched along with bay 63-2521 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Allanore, Y; de Oliveira Pena, J; Denton, C; Distler, O; Khanna, D; Matucci-Cerinic, M; Pope, J	1

Trials

1 trial(s) available for carbon monoxide and bay 63-2521

Article	Year
RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis. Respiratory medicine, 2017, Volume: 122 Suppl 1 Topics: Carbon Monoxide; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Diffusing Capacity; Pulmonary Embolism; Pyrazoles; Pyrimidines; Quality of Life; Scleroderma, Diffuse; Scleroderma, Systemic; Skin; Skin Diseases; Soluble Guanylyl Cyclase; Treatment Outcome; Vital Capacity	2017

Article

Year

RISE-SSc: Riociguat in diffuse cutaneous systemic sclerosis.

Respiratory medicine, 2017, Volume: 122 Suppl 1

Topics: Carbon Monoxide; Dose-Response Relationship, Drug; Double-Blind Method; Enzyme Activators; Female; Humans; Hypertension, Pulmonary; Male; Pulmonary Diffusing Capacity; Pulmonary Embolism; Pyrazoles; Pyrimidines; Quality of Life; Scleroderma, Diffuse; Scleroderma, Systemic; Skin; Skin Diseases; Soluble Guanylyl Cyclase; Treatment Outcome; Vital Capacity

2017